學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Monosha Biotech: Growth Challenges of a Social Enterprise Brand
內容大綱
Monosha Biotech (MB), a social start-up in Baruipur, West Bengal, India, was founded in 2017 to tackle a significant public health issue: snakebites. India had the highest number of snakebite fatalities globally, and the efficacy of anti-snake venom (ASVs) varied significantly depending on the snake's location. As the prominent snake-venom manufacturer was headquartered in southern India, the existing ASVs had been customized to provide optimal effectiveness in the southern part of the country, and this left individuals in other regions across the country exposed and in danger when they suffered snake bites, consequently adding to the high fatality rate. MB started commercial snake-venom production in 2021, after getting all the necessary clearance and approval from the authorities. Despite the company's commercial success, in 2023, the company's founders had concerns about the future of their market expansion, particularly regarding the company's scalability and potential for continued growth. Their task was difficult, as they had to confront two significant challenges. First, how could they create an authentic brand with the company's vision, mission, and value proposition as a social enterprise in mind? Second, what alternative for expansion in the anti-snake-venom market would be suitable to ensure further growth?